Please use this identifier to cite or link to this item:
Title: Usefulness of oral beclometasone dipropionate in the treatment of active ulcerative colitis in clinical practice: The RECLICU Study
Authors: Nunes, T
Barreiro-de Acosta, M
Nos, P
Marin-Jiménez, I
Bermejo, F
Ceballos Santos, Daniel Sebastián 
Iglesias, E
Gomez-Senent, S
Torres, Y
Ponferrada, A
Arevalo, JA
Hernandez, V
Calvet, X
Ginard, D
Monfort, D
Chaparro, M
Manceñido, N
Domínguez-Antonaya, M
Villalón, C
Perez-Calle, JL
Muñoz, C
Nuñez, H
Carpio, D
Aramendiz, R
Bujanda, L
Estrada-Oncins, S
Hermida, C
Barrio, J
Casis, MB
Dueñas-Sadornil, MC
Fernández, L
Calvo-Cenizo, MM
Botella, B
de Francisco, R
Ayala, E
Sans, M
UNESCO Clasification: 32 Ciencias médicas
3205 Medicina interna
3208 Farmacodinámica
Keywords: Beclometasone dipropionate
Ulcerative colitis
Issue Date: 2010
Journal: Journal of Crohn's and Colitis 
Abstract: Background: Beclometasone dipropionate (BDP) is a relatively new topically acting oral steroid to treat mild to moderately active ulcerative colitis (UC). We estimate that 20,000 patients have received oral BDP in Spain in the last two years. Our aim was to evaluate the efficacy and safety of oral BDP in clinical practice. Methods: Retrospective and multicenter study that included 434 patients with active UC treated with BDP. The partial Mayo Clinic score (pMS, 0-9) was used to measure disease activity. Remission was defined as post-treatment pMS of 0 or 1; response as a decrease in pMS of 3 points or 2 points and > 30%, and failure as lack of remission or response. Results: BDP dose was 5. mg/day in 88% of patients and mean treatment duration was 6.2. weeks. BDP achieved remission in 44.4%, response in 22.3% and failed in 33.2% of patients. Mean pMS decreased from 4.9 ± 1.3 to 2.4 ± 2.3 (p. < 0.0001). Remission rate was higher in mild and moderate than in severe UC (p. < 0.043) and tended to be higher in left-sided and extensive UC than in proctitis (p. < 0.06). Failure was less frequent in patients treated for > 4. weeks (p. < 0.02). Mild adverse events were reported in 7.6% of patients. Conclusion: BDP induces response or remission in two thirds of active UC patients, with a good safety profile. Patients with mild to moderate, left-sided or extensive UC, receiving BDP for more than 4. weeks are most likely to benefit from this treatment. © 2010 European Crohn's and Colitis Organisation.
ISSN: 1873-9946
DOI: 10.1016/j.crohns.2010.07.003
Source: Journal of Crohn's and Colitis [1873-9946], v. 4(6), pp. 629-636 (Diciembre 2010)
Appears in Collections:Artículos
Show full item record

Google ScholarTM




Export metadata

Items in accedaCRIS are protected by copyright, with all rights reserved, unless otherwise indicated.